Katherine Wavering
Family · Rockwall, TXNPI 1295222149
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Biohaven Pharmaceutical Holding Company Ltd. at 51.1% of the total. Reporting peaked in 2022 at $1,303 and has fallen 97.3% since, to $35 in 2023.
Across 77 payments — averaging $32.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$1K
- Novo Nordisk$159
- AbbVie$135
- Pfizer$132
- Astellas Pharma US Inc$100
- Amarin Pharma, Inc.$78
- plus $610 from 19 others
What the payments were for
- Consulting fees$80032%
- Travel & lodging$30412%
- Food & beverage$1,28052%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $1,270 |
| Novo Nordisk | 12 | $159 |
| AbbVie | 9 | $135 |
| Pfizer | 8 | $132 |
| Astellas Pharma US Inc | 1 | $100 |
| Amarin Pharma, Inc. | 4 | $78 |
| Amgen | 3 | $70 |
| Merck | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Lilly USA, LLC | 4 | $49 |
| Eisai Inc. | 3 | $45 |
| Abbott | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Novartis | 2 | $24 |
| GSK | 2 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,104
How this compares
$2,484 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 88 | $462 |
Paid to pharmacies, not to this prescriber.
Other family in Rockwall
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.